Ratings
0
Nobody has rated this yet. Be the first!
Works
4
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
